Highest-materiality recent filing
Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026
CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.
Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026
API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.
Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.
Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.
Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track
Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028
Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.
Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes
Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.
First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).
Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC
Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.
Allarity Therapeutics enters $6M equity line of credit with Tumim Stone Capital
Company may sell up to $6M of common stock at 95-97% of VWAP discount.
Additional Closing on Dec 23, 2025; 255,103 shares at $0.98/share for gross proceeds of ~$250,000.
Allarity Therapeutics CFO Jeffrey Ervin moves to full-time; gets $367.7K salary, $160K RSUs
CFO Jeffrey S. Ervin transitioned from part-time to full-time effective December 3, 2025 under new employment agreement.
Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.
Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1
CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.
Allarity Therapeutics raises ~$2.5M in private placement, with option for additional $7.5M
Sold 1,562,500 shares at $1.60/sh and/or pre-funded warrants at $1.5999 for gross proceeds ~$2.5M.
Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer
FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.
Allarity Therapeutics announces DRP licensing and lab services deal with EU biotech
Non-exclusive global license to selected DRP algorithms in breast cancer granted to an undisclosed EU-based biotech company.
Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025
CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.
Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic
IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.
Allarity dosed second patient in new Phase 2 stenoparib trial for advanced ovarian cancer
Second patient dosed in new Phase 2 trial of stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
Allarity shareholders reject equity plan increase and officer exculpation
Thomas H. Jensen re-elected as Class III director with 1,673,698 for, 265,465 withheld.
Allarity Therapeutics appoints Jesper Høiland to board, replacing Joseph Vazzano
Joseph Vazzano resigned as director effective June 30, 2025.
Collaboration aims to clarify contributions of PARP inhibition and WNT pathway modulation to stenoparib's anticancer effects.
Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer
First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.
On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025.
On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025.
Max materiality 0.75 · Median 0.60 · Most common event other_material